Eleven Biotherapeutics Inc. (EBIO)

0.9626 +0.0225 (+2.393%)

IEX Real-Time Price

February 23, 2018 EST.

NASDAQ Global Market : Healthcare

Prev Close 0.9401

Price Open 0.9718

Volume: 398,842

Avg Volume: 927,408

Market Cap: 30.64M

P/E Ratio -0.86

52 Wk Range 0.6201-2.54



EBIO Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-01-31
30.79M
2.8M
2.49
9.09%

2018-01-12
30.79M
1.64M
1.04
5.34%

2017-12-29
30.79M
1.89M
0.88
6.15%

2017-12-15
30.79M
1.8M
1.04
5.86%




EBIO Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-03-23
Q4 2017
N/A
0.00 (0)
0.00
0.00

2017-11-20
Q3 2017
BTO
0.00 (0)
-0.37
0.00

2017-08-14
Q2 2017
BTO
0.00 (0)
-0.30
0.00

2017-05-04
Q1 2017
BTO
0.00 (0)
-0.25
0.00

News

Eleven Biotherapeutics (EBIO) Presents At BIO CEO & Investor Conference - Slideshow (2018-02-13 14:12 SeekingAlpha)

The following slide deck was published by Eleven Biotherapeutics, Inc. in conjunction with this Read more …

 

Eleven Biotherapeutics Appoints Richard Fitzgerald as Chief Financial Officer (2018-01-24 15:12 Business Wire)

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Richard F. Fitzgerald has been appointed as full time Chief Financial Officer of the Company….

 

Eleven Biotherapeutics to Present at Biotech Showcase 2018 (2018-01-02 16:30 Business Wire)

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive Officer, will present a company overview at the …

 

Eleven Biotherapeutics Announces Chief Scientific Officer to Chair a Session at the Antibody Engineering and Therapeutics Meeting (2017-12-13 07:00 Business Wire)

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Dr. Gregory Adams, Chief Scientific Officer, will chair a session focused on antibody drug co…

 

Eleven Biotherapeutics to Present at the LD Micro Main Event 2017 (2017-11-30 16:30 Business Wire)

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive Officer, will present a company overview at the …

 

Eleven Biotherapeutics Reports Third Quarter 2017 Financial Results (2017-11-20 08:30 Business Wire)

-- Phase 3 Enrollment on Track to Complete in Q1 2018 -- -- Topline 3-Month Data from Phase 3 Trial of Vicinium on Track for Mid-2018 -- -- Strengthened Balance Sheet with $8.0 million Capital Raise -- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical…

 


Statistics

Shares Outstanding: 31.83M

Top 15 Institution Percent: 4.80

Price To Sales: 70.41

Price To Book: 1.75

Revenue: 1.25M

Gross Profit: N/A

Cash: 72.70M

Debt: N/A

Return On Assets: -33.48

Return On Equity: -86.20

Profit Margin: N/A

Price History

Beta: 3.16

50-day Moving Avg: 0.87

200-day Moving Avg: 1.18

YTD Change: 15.98

5-day Change: 6.96

1-month Change: 9.39

3-month Change: 49.24

6-month Change: -0.76

1-year Change: -52.35

Revenue Per Share: 0.00

Revenue Per Employee: 35714.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Eleven Biotherapeutics Inc.

Exchange: NASDAQ Global Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.elevenbio.com

Eleven Biotherapeutics Inc is a biotechnology-based firm in the United States. It is engaged in the development of therapeutics to cure diseases related to the eye.